Tricida Granted Additional U.S. Patent Covering Composition of Matter of Veverimer
March 03 2021 - 8:30AM
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused
on the development and commercialization of its investigational
drug candidate, veverimer, a non-absorbed, orally-administered
polymer designed to treat metabolic acidosis in patients with
chronic kidney disease (CKD), today announced today that U.S.
patent number 10,934,380, entitled “CROSSLINKED POLY(ALLYLAMINE)
POLYMER COMPOSITIONS” has issued from the United States Patent and
Trademark Office. The newly issued patent covers additional
composition of matter claims for veverimer to 2038 and extends the
Tricida patent portfolio, which is solely owned by the company, to
a total of 210 patents in 49 different countries, including two
previously issued U.S. composition of matter patents and four
issued U.S. method of treatment patents which provide protection to
2034. In addition, Tricida holds three issued European Patent
Office patents providing patent protection until 2034 and two
additional issued patents providing protection until 2035 in
Europe, as well as patent protection expected to provide protection
for veverimer until at least 2034 in Australia, China, Hong Kong,
Israel, Japan, Mexico and certain other markets. Tricida solely
owns other patent applications relating to veverimer that are
currently pending in Australia, Brazil, Canada, China, Europe, Hong
Kong, India, Israel, Japan, Mexico, Republic of Korea, Russia, and
the United States.
“This new composition of matter patent will
enable us to fully capitalize on veverimer’s U.S. potential into
2038,” said Gerrit Klaerner, Ph.D., Tricida’s Chief Executive
Officer and President. “While our focus today is on the continued
successful execution of the VALOR-CKD trial, we are not losing site
of the commercial opportunity for veverimer. This patent adds four
years of additional patent protection to our timeline to obtain the
full value of veverimer.”
About Tricida
Tricida, Inc. is a pharmaceutical company
focused on the development and commercialization of its
investigational drug candidate, veverimer (TRC101), a non-absorbed,
orally-administered polymer designed to treat metabolic acidosis in
patients with CKD. Tricida is currently conducting a renal outcomes
clinical trial, VALOR-CKD, to determine if veverimer slows CKD
progression in patients with metabolic acidosis associated with
CKD. There are no FDA-approved treatments for chronic metabolic
acidosis, a condition commonly caused by CKD that is believed to
accelerate the progression of kidney deterioration. It is estimated
to pose a health risk to approximately three million patients with
CKD in the United States.
For more information about Tricida, please
visit www.Tricida.com.
Cautionary Note on Forward-Looking
Statements
This press release includes forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements relate to expectations concerning
matters that are not historical facts. Words such as “projects,”
“believes,” “anticipates,” “plans,” “expects,” “intends,” “may,”
“will,” “could,” “should,” “would,” and similar words and
expressions are intended to identify forward-looking statements.
Any statements contained herein which do not describe historical
facts, including the Company’s plans and expectations with regard
to the potential issuance of additional patents to the Company in
the U.S. and other countries and the anticipated period of
protection provided by such patents, if issued, are forward-looking
statements which involve risks and uncertainties that could cause
actual results to differ materially from those discussed in such
forward-looking statements. Such risks and uncertainties include,
without limitation, whether the FDA will accept the Company’s
resubmission of an NDA for veverimer; the timing of the FDA’s
approval of veverimer, if at all; the potential availability of the
Accelerated Approval Program and the approvability of veverimer
under that program; the Company’s plans and expectations with
regard to its interactions with the FDA; the Company’s plans and
expectations for VALOR-CKD and future clinical and product
development milestones; the Company’s financial projections and
cost estimates; the enforceability of our patent estate and our
ability to defend against infringement of our patents; and risks
associated with the Company’s business prospects, financial results
and business operations. These and other factors that may affect
the Company’s future business prospects, results and operations are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s most recent Annual Report filed on Form 10-K and the
subsequently filed Quarterly Report(s) on Form 10-Q. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Except as required
by applicable law, the Company does not intend to update any of the
forward-looking statements to conform these statements to actual
results, later events or circumstances or to reflect the occurrence
of unanticipated events.
Contact:Jackie Cossmon, IRCTricida, Inc.Senior
Vice President ofInvestor Relations and
CommunicationsIR@Tricida.com
Tricida (NASDAQ:TCDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tricida (NASDAQ:TCDA)
Historical Stock Chart
From Sep 2023 to Sep 2024